Christina Bohk-Ewald1,2, Christian Dudel1, Mikko Myrskylä1,2. 1. Max Planck Institute for Demographic Research, Rostock, Germany. 2. Center for Social Data Science, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Understanding how widely COVID-19 has spread is critical information for monitoring the pandemic. The actual number of infections potentially exceeds the number of confirmed cases. DEVELOPMENT: We develop a demographic scaling model to estimate COVID-19 infections, based on minimal data requirements: COVID-19-related deaths, infection fatality rates (IFRs), and life tables. As many countries lack IFR estimates, we scale them from a reference country based on remaining lifetime to better match the context in a target population with respect to age structure, health conditions and medical services. We introduce formulas to account for bias in input data and provide a heuristic to assess whether local seroprevalence estimates are representative for the total population. APPLICATION: Across 10 countries with most reported COVID-19 deaths as of 23 July 2020, the number of infections is estimated to be three [95% prediction interval: 2-8] times the number of confirmed cases. Cross-country variation is high. The estimated number of infections is 5.3 million for the USA, 1.8 million for the UK, 1.4 million for France, and 0.4 million for Peru, or more than one, six, seven and more than one times the number of confirmed cases, respectively. Our central prevalence estimates for entire countries are markedly lower than most others based on local seroprevalence studies. CONCLUSIONS: The national infection estimates indicate that the pandemic is far more widespread than the numbers of confirmed cases suggest. Some local seroprevalence estimates largely deviate from their corresponding national mean and are unlikely to be representative for the total population.
BACKGROUND: Understanding how widely COVID-19 has spread is critical information for monitoring the pandemic. The actual number of infections potentially exceeds the number of confirmed cases. DEVELOPMENT: We develop a demographic scaling model to estimate COVID-19infections, based on minimal data requirements: COVID-19-related deaths, infection fatality rates (IFRs), and life tables. As many countries lack IFR estimates, we scale them from a reference country based on remaining lifetime to better match the context in a target population with respect to age structure, health conditions and medical services. We introduce formulas to account for bias in input data and provide a heuristic to assess whether local seroprevalence estimates are representative for the total population. APPLICATION: Across 10 countries with most reported COVID-19deaths as of 23 July 2020, the number of infections is estimated to be three [95% prediction interval: 2-8] times the number of confirmed cases. Cross-country variation is high. The estimated number of infections is 5.3 million for the USA, 1.8 million for the UK, 1.4 million for France, and 0.4 million for Peru, or more than one, six, seven and more than one times the number of confirmed cases, respectively. Our central prevalence estimates for entire countries are markedly lower than most others based on local seroprevalence studies. CONCLUSIONS: The national infection estimates indicate that the pandemic is far more widespread than the numbers of confirmed cases suggest. Some local seroprevalence estimates largely deviate from their corresponding national mean and are unlikely to be representative for the total population.
Authors: Marina Pollán; Beatriz Pérez-Gómez; Roberto Pastor-Barriuso; Jesús Oteo; Miguel A Hernán; Mayte Pérez-Olmeda; Jose L Sanmartín; Aurora Fernández-García; Israel Cruz; Nerea Fernández de Larrea; Marta Molina; Francisco Rodríguez-Cabrera; Mariano Martín; Paloma Merino-Amador; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Raquel Yotti Journal: Lancet Date: 2020-07-06 Impact factor: 79.321
Authors: Robert Verity; Lucy C Okell; Ilaria Dorigatti; Peter Winskill; Charles Whittaker; Natsuko Imai; Gina Cuomo-Dannenburg; Hayley Thompson; Patrick G T Walker; Han Fu; Amy Dighe; Jamie T Griffin; Marc Baguelin; Sangeeta Bhatia; Adhiratha Boonyasiri; Anne Cori; Zulma Cucunubá; Rich FitzJohn; Katy Gaythorpe; Will Green; Arran Hamlet; Wes Hinsley; Daniel Laydon; Gemma Nedjati-Gilani; Steven Riley; Sabine van Elsland; Erik Volz; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; Christl A Donnelly; Azra C Ghani; Neil M Ferguson Journal: Lancet Infect Dis Date: 2020-03-30 Impact factor: 25.071
Authors: Timothy W Russell; Joel Hellewell; Christopher I Jarvis; Kevin van Zandvoort; Sam Abbott; Ruwan Ratnayake; Stefan Flasche; Rosalind M Eggo; W John Edmunds; Adam J Kucharski Journal: Euro Surveill Date: 2020-03
Authors: Sayed Ataullah Saeedzai; Mohammad Nadir Sahak; Fatima Arifi; Eman Abdelkreem Aly; Margo van Gurp; Lisa J White; Siyu Chen; Amal Barakat; Giti Azim; Bahara Rasoly; Soraya Safi; Jennifer A Flegg; Nasar Ahmed; Mohmmad Jamaluddin Ahadi; Niaz M Achakzai; Alaa AbouZeid Journal: BMJ Open Date: 2022-07-27 Impact factor: 3.006
Authors: Yannis Herrmann; Tim Starck; Niall Brindl; Philip J Kitchen; Lukas Rädeker; Jakob Sebastian; Lisa Köppel; Frank Tobian; Aurélia Souares; André L Mihaljevic; Uta Merle; Theresa Hippchen; Felix Herth; Britta Knorr; Andreas Welker; Claudia M Denkinger Journal: PLoS One Date: 2021-07-30 Impact factor: 3.240